Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.
B-cell Chronic Lymphocytic Leukemia
BIOLOGICAL: Alemtuzumab
Objective Response Rate(ORR), Objective Response Rate was defined as the proportion of patients who have CR, PR during the study as evaluated according to National Comprehensive Cancer Network(NCCN) guideline 2010 response criteria. Response categories include Complete Response(CR) and Partial Response(PR).

ORR=CR+PR, up to 1 year
Progression-Free Survival, Progression-Free Survival was defined as the time from randomization to disease progression (PD) or death due to any cause, whichever comes first., up to 1 year|Disease Control Rate(DCR), Patients were evaluated according to National Comprehensive Cancer Network(NCCN) guideline 2010 response criteria. The best response observed during the study is summarized. Response categories include Complete Response(CR), Partial Response(PR) and Stable Disease(SD).

DCR=CR+PR+SD, up to 1 year|Duration of Response(DOR), Duration of response was analyzed for patients who achieved a complete release(CR) or partial release(PR) and was defined as the time from the first date of documented response to the date of disease progression or death due to any cause., up to 1 year|Overall Survival, Overall Survival was defined as the duration from randomization to death due to any cause., up to 1 year|Summary of patients with Adverse Events(AEs), Analysis of patients with adverse experiences according to CTCAE Version 4., up to 1 year
This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.